Literature DB >> 2177093

Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen.

G Goodarzi1, S C Gross, A Tewari, K Watabe.   

Abstract

The effect of a series of antisense oligodeoxyribonucleotide [oligo(dN)] on the expression of the surface antigen (HBsAg) gene of human hepatitis B virus (HBV) was examined using hepatocellular carcinoma cells that contain integrated HBV genomes. Of a number of antisense oligo(dN)s tested, synthetic 15-mers directed at the cap site of mRNA and regions of the translational initiation site of the HBsAg gene were found to be highly effective and inhibited viral gene expression by as much as 96%. The inhibition was specific to the HBsAg gene and appeared to be at the level of translation. These results suggest a therapeutic potential for antisense oligo(dN) in the treatment of patients who are chronically infected with HBV.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2177093     DOI： 10.1099/0022-1317-71-12-3021

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  13 in total

Review 1.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  An Arabidopsis mutant with a reduced level of cab140 RNA is a result of cosuppression.

Authors:  J A Brusslan; G A Karlin-Neumann; L Huang; E M Tobin
Journal:  Plant Cell       Date:  1993-06       Impact factor: 11.277

4.  Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol.

Authors:  Xian-Rong Qi; Wen-Wei Yan; Jing Shi
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

5.  Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers.

Authors:  A Bielinska; J F Kukowska-Latallo; J Johnson; D A Tomalia; J R Baker
Journal:  Nucleic Acids Res       Date:  1996-06-01       Impact factor: 16.971

Review 6.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield.

Authors:  Z Xing; J L Whitton
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Antisense therapy of hepatitis B virus infection.

Authors:  W B Offensperger; S Offensperger; H E Blum
Journal:  Mol Biotechnol       Date:  1998-04       Impact factor: 2.695

Review 9.  Molecular therapeutic strategies in hepatitis B virus infection.

Authors:  W B Offensperger; H E Blum; W Gerok
Journal:  Clin Investig       Date:  1994-10

10.  In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

Authors:  W B Offensperger; S Offensperger; E Walter; K Teubner; G Igloi; H E Blum; W Gerok
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.